Importantly, despite retention of the EGFR mutation, the tumor was resistant to both EGFR-TKIs and standard SCLC chemotherapy, underscoring the loss of EGFR dependence and the aggressive biology of transformed SCLC compared with de novo disease [30]. The gene discussed is EGFR; the disease is neoplasm.